Corticosteroid treatment is associated with increased filamentous fungal burden in allergic fungal disease - 04/08/18
![](/templates/common/images/mail.png)
Abstract |
Background |
Allergic diseases caused by fungi are common. The best understood conditions are allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Our knowledge of the fungal microbiome (mycobiome) is limited to a few studies involving healthy individuals, asthmatics, and smokers. No study has yet examined the mycobiome in fungal lung disease.
Objectives |
The main aim of this study was to determine the mycobiome in lungs of individuals with well-characterized fungal disease. A secondary objective was to determine possible effects of treatment on the mycobiome.
Methods |
After bronchoscopy, ribosomal internal transcribed spacer region 1 DNA was amplified and sequenced and fungal load determined by real-time PCR. Clinical and treatment variables were correlated with the main species identified. Bronchopulmonary aspergillosis (n = 16), severe asthma with fungal sensitization (n = 16), severe asthma not sensitized to fungi (n = 9), mild asthma patients (n = 7), and 10 healthy control subjects were studied.
Results |
The mycobiome was highly varied with severe asthmatics carrying higher loads of fungus. Healthy individuals had low fungal loads, mostly poorly characterized Malasezziales. The most common fungus in asthmatics was Aspergillus fumigatus complex and this taxon accounted for the increased burden of fungus in the high-level samples. Corticosteroid treatment was significantly associated with increased fungal load (P < .01).
Conclusions |
The mycobiome is highly variable. Highest loads of fungus are observed in severe asthmatics and the most common fungus is Aspergillus fumigatus complex. Individuals receiving steroid therapy had significantly higher levels of Aspergillus and total fungus in their bronchoalveolar lavage.
Le texte complet de cet article est disponible en PDF.Key words : Lung mycobiome, Aspergillus, steroid, antifungal, allergic bronchopulmonary aspergillosis, asthma
Abbreviations used : ABPA, BAL, ICS, ITS, OCS, RT-PCR, SA, SAFS
Plan
M.B. and P.B. receive support from Medical Research Council (MRC) grant MR/M02010X/1. M.F., M.B., and P.B. were funded by EU Framework 7 (FP7-2007-2013) under grant agreement HEALTH-F2-2010-260338 “ALLFUN.” |
|
Disclosure of potential conflict of interest: L. Chishimba has received grants from the University of Manchester, National Aspergillosis Centre, and Novartis; has received travel support from AstraZeneca and GlaxoSmithKline; and has received payment for lectures from Novartis and AstraZeneca. R. M. Niven has consultant arrangements with AstraZeneca, Boehringer, Boston, Chiesi, Novartis, Roche, TEVA Pharmaceutical Industries, and Vectura; has received payment for lectures from AstraZeneca, Boehringer, Boston, Chiesi, GlaxoSmithKline, Napp, Novartis, Roche, and TEVA; and has received travel support from Boehringer, Chiesi, Napp, Novartis, and TEVA. M. Bromley has a board membership with Syngenics Limited; has consultant arrangements with Synergy Health PLC (also known as Genon Laboratories Limited); is employed by the University of Manchester and Lariat Consulting LLP; and has received grants from the Biotechnology and Biological Sciences Research Council, Wellcome Trust, the Medical Research Council, the European Union, Innovate UK, DuPont, Hans Knoll Institute, and F2G Limited. L. Smyth is employed by University of Salford and has received a grant from Kidscan. D. W. Denning has received grants from Pfizer, Gilead, Merck Sharp Dohme, and Astellas; has received personal fees from Pfizer, Gilead, Merck Sharp Dohme, Basilea, Pulmocide, Dynamiker, Cidara, Syncexis, Astellas, Biosergen, Quintilles, Pulmatrix, and Pulmocide; and has a patent for assays for fungal infection. P. Bowyer has received a grant from the Medical Research Council (MR/M02010X/1) and has received payment for lectures from Gilead Ltd. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 2
P. 407-414 - août 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?